PCM
CSTL icon

Pentwater Capital Management’s Castle Biosciences CSTL Stock Holding History

Pentwater Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,000
Closed -$367K – 243
2021
Q2 		$367K Buy
+5,000
New +$330K ﹤0.01% 264

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Pentwater Capital Management's CSTL Position: Q3 2021 in Review

Pentwater Capital Management sold out of Castle Biosciences (CSTL) in Q3 2021, closing a stake of 5,000 shares — an estimated $367K sold.

Pentwater Capital Management first reported a position in CSTL in Q2 2020 and held it in 5 quarters. The position peaked at $672K in Q4 2020. 188 funds tracked by Wall St. Rank hold CSTL as of Q3 2021.

  • Pentwater Capital Management reported no remaining Castle Biosciences position as of Q3 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 5,000 Castle Biosciences shares in Q3 2021, an estimated $367K.
  • Pentwater Capital Management first reported a position in Castle Biosciences in Q2 2020 and held it in 5 quarters.
  • Pentwater Capital Management's Castle Biosciences position peaked at $672K in Q4 2020.
  • 188 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.